, Volume 12, Issue 4, pp 261-268
Date: 09 Oct 2013

Current and Future Treatment of Chronic Hepatitis C Genotype 2 and 3

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Hepatitis C genotype 2 and 3 accounts for a significant number of HCV infected patients around the world. The combination of peginterferon alpha and ribavirin (PEG-IFN/RBV) demonstrated favourable results in treatment of genotype 2 and 3 infected patients with sustained virological responses rates of up to 80 %. In 2011, the first direct acting antivirals (DAA) have been approved but so far only for genotype 1. Several other antivirals are currently tested in clinical trials. Two compounds demonstrated promising results in patients with genotype 2 and 3. Sofosbuvir (SOF), a NS5B polymerase inhibitor, proved to be effective even without PEG-IFN and approval of an interferon-free regimen is foreseeable. Alisporivir (ALV), a host-targeting antiviral demonstrated encouraging results in phase-I and -II trials in genotype 2 and 3 patients and offers a new mechanism of action. However, further trials are needed to prove long-term safety and the efficacy in difficult-to-treat patients.